Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial Meeting Abstract
| Authors: | O'Reilly, E. M.; Melisi, D.; Macarulla, T.; Pazo Cid, R. A.; Chandana, S. R.; De La Fouchardiere, C.; Dean, A. P.; Kiss, I.; Lee, W. J.; Goetze, T. O.; Van Cutsem, E.; Paulson, S.; Bekaii-Saab, T. S.; Pant, S.; Hubner, R.; Xiao, Z.; Chen, H.; Benzaghou, F.; Wainberg, Z. A. |
| Abstract Title: | Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4006 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4006 -- This meeting was also held virtually -- Source: Cinahl |
